Direxion Daily Pharmaceutical & Medical Bull 3X Shares Declares Quarterly Distribution of $0.0131

Seeking AlphaDec 24 21:47

Bristol-Myers Squibb (BMY.US) TYK2 inhibitors have achieved the primary endpoints in two key phase 3 clinical trials.

Bristol-Myers Squibb (BMY.US) announced today the positive results of the POETYK PsA-1 and POETYK PsA-2 trials. These two key Phase 3 clinical trials evaluated the efficacy and safety of the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) in adult patients with active psoriatic arthritis (PsA).

Zhitong FinanceDec 24 09:19

Schwab US Dividend Equity ETF Reverses In December: What's Going On?

BenzingaDec 24 04:53

The bad news from the U.S. stock market may have been fully digested! It's time for investors to focus on this type of Stocks.

The bad news may have already been fully absorbed, and factors such as profits, valuations, and long-term underperformance are expected to help value stocks catch up.

Baron ChineseDec 23 22:32

Viatris Issues Statement Regarding Receipt Of Warning Letter And Import Alert For Indore, India Facility; The Import Alert Affects 11 Actively Distributed Products That Will No Longer Be Accepted Into The U.S. Until The Warning Letter Is Lifted

BenzingaDec 23 21:26

Bristol Myers Squibb's Sotyktu Shows Results in Psoriatic Arthritis Trials

BenzingaDec 23 20:00